Ian Barlow - Smith Nephew Non-Executive Independent Director
| SNNUF Stock | USD 11.93 0.14 1.16% |
Director
Mr. Ian Edward Barlow was Senior Independent NonExecutive Director of Smith Nephew PLC. Ian is a Chartered Accountant with considerable financial experience both internationally and in the UK. He was a Partner at KPMG, latterly Senior Partner, London, until 2008. At KPMG, he was Head of UK tax and legal operations. Previously he was Chairman of WSP Group plc, and is currently NED and Chairman of the Audit Committees of The Brunner Investment Trust PLC, Foxtons Group plc and UrbanCivic plc. Ians longstanding financial and auditing career and extensive board experience add value to his role as a member of the Audit Committee. As a member of the Ethics Compliance Committee, he has managed to coordinate an oversight role of both Committees. This was invaluable when commencing his role as Senior Independent Director with effect from 6 April 2017. Ians first board evaluation is discussed in the corporate governance statement. since 2017.
| Age | 65 |
| Tenure | 7 years |
| Phone | 44 1923 477 100 |
| Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Michael Leavitt | Medtronic PLC | 69 | |
| Peter Munson | Orthopediatrics Corp | 49 | |
| Lynn Bleil | Sonova Holding AG | 54 | |
| Martin Maxwell | Integer Holdings Corp | 62 | |
| Thomas Bernhardsgruetter | Sonova Holding AG | N/A | |
| Andrea Saia | LivaNova PLC | 60 | |
| Alan Levine | Axogen Inc | 50 | |
| Mark Foley | Glaukos Corp | 55 | |
| Martha Aronson | CONMED | 53 | |
| Cheryl Capps | Integer Holdings Corp | 59 | |
| Kevin Unger | Orthopediatrics Corp | 46 | |
| Andreas Rihs | Sonova Holding AG | 72 | |
| Craig Arnold | Medtronic PLC | 60 | |
| Oscar Moralez | Orthopediatrics Corp | 52 | |
| Robert Rudelius | Axogen Inc | 62 | |
| Randall Hogan | Medtronic PLC | 64 | |
| Kendall Powell | Medtronic PLC | 66 | |
| Carlton Highsmith | Paragon 28 | 63 | |
| Mike Donovan | Axogen Inc | 53 | |
| James Hinrichs | Integer Holdings Corp | 53 | |
| John Andres | Apyx Medical | 59 | |
Management Performance
| Return On Equity | 0.0925 | |||
| Return On Asset | 0.0425 |
Smith Nephew plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Namal Nawana, CEO, Executive Director | ||
| Michael Friedman, Non-Executive Independent Director | ||
| Diogo MoreiraRato, President - Europe and Canada | ||
| Alison Parkes, Chief Officer | ||
| Skip Kiil, President - Orthopedics | ||
| Erik Engstrom, Non-Executive Director | ||
| Deepak Nath, CEO Director | ||
| Matthew Stober, President - Global Operations | ||
| Marc Owen, Non-Executive Director | ||
| AnneFrancoise Nesmes, CFO Director | ||
| Helen Barraclough, Company Counsel | ||
| Rodrigo Bianchi, President IRAMEA | ||
| Brian Larcombe, Senior Independent Non-Executive Director | ||
| Elga Lohler, Chief Human Resource Officer | ||
| Bradley Cannon, Sports Orthopaedics | ||
| Gunthorp Oie, IR Contact Officer | ||
| Roland Diggelmann, Non-Executive Director | ||
| Helen Maye, Chief Human Resources Officer | ||
| Vinita Bali, Non-Executive Director | ||
| Simon Fraser, President - Advanced Wound Management | ||
| Massimiliano Colella, President Europe - Middle East and Africa | ||
| Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
| Graham Baker, CFO, Executive Director | ||
| Cathy ORourke, Chief Legal and Compliance Officer | ||
| Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
| Joe Metzger, VP Communications | ||
| Cyrille Petit, Chief Corporate Development Officer | ||
| Julie Brown, CFO, Director and Member of Disclosures Committee | ||
| Glenn Warner, President - Advanced Wound Management | ||
| Robin Freestone, Non-Executive Director | ||
| Paul Connolly, Pres Operations | ||
| Virginia Bottomley, Non-Executive Independent Director | ||
| Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
| Angie Risley, Non-Executive Director | ||
| Mark Gladwell, President - Global Operations | ||
| Andrew Swift, VP Relations | ||
| Vasant Padmanabhan, President - Research & Development | ||
| Michael Frazzette, President - Advanced Surgical Devices | ||
| Joseph Papa, Non-Executive Independent Director | ||
| Ingeborg Oie, VP, Investor Relations | ||
| Susan Swabey, Company Secretary | ||
| Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
| Philip Cowdy, Chief Officer | ||
| Gordon Howe, President of Global Operations | ||
| John Campo, Chief Legal Officer | ||
| Brad Cannon, President Europe and Canada | ||
| Ian Barlow, Non-Executive Independent Director | ||
| Catheryn ORourke, Chief Legal Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0925 | |||
| Return On Asset | 0.0425 | |||
| Profit Margin | 0.1 % | |||
| Operating Margin | 0.14 % | |||
| Current Valuation | 14.08 B | |||
| Shares Outstanding | 873.35 M | |||
| Shares Owned By Insiders | 0.17 % | |||
| Shares Owned By Institutions | 52.60 % | |||
| Price To Earning | 23.41 X | |||
| Price To Book | 2.12 X |
Currently Active Assets on Macroaxis
| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink | |
| XLM | Stellar | |
| CRO | Cronos |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Smith Pink Sheet analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |